NAMSW

アフターアワーズ： 6.95

Newamsterdam Pharma Company N V (NAMSW)

Relative Volume:

ネットキャッシュフロー:

Newamsterdam Pharma Company N V Stock (NAMSW) Company Profile

Newamsterdam Pharma Company N V

31 35 206 2971

Gooimeer 2-35, Naarden

NAMSW's Discussions on Twitter

Newamsterdam Pharma Company N V (NAMSW) 最新ニュース

Newamsterdam Pharma Company N V (NAMSW) 財務データ

Newamsterdam Pharma Company N V (NAMSW) の財務データはありません。詳細については、他の銘柄を確認してください。

Newamsterdam Pharma Company N V (NAMSW)

Newamsterdam Pharma Company N V Stock (NAMSW) Company Profile

Newamsterdam Pharma Company N V (NAMSW) 最新ニュース

NewAmsterdam Pharma (NASDAQ:NAMS) Receives Average Rating of "Buy" from Brokerages - MarketBeat

NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - StockTitan

NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Yahoo Finance UK

NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Yahoo Finance

NewAmsterdam Pharma (NASDAQ:NAMS) Earns "Outperform" Rating from Royal Bank of Canada - MarketBeat

NewAmsterdam Pharma (NASDAQ:NAMS) Short Interest Up 20.7% in August - MarketBeat

NAMSWNewAmsterdam Pharma Company N.V. Warrant Latest Stock News & Market Updates - StockTitan

Buying Buzz: NewAmsterdam Pharma Company NV [NAMS] Chief Executive Officer Davidson Michael H. purchases 5,000 shares of the company – Knox Daily - Knox Daily

NewAmsterdam Pharma to Participate in Upcoming Investor Conferences in September - Yahoo Finance

NewAmsterdam Pharma to Participate in Upcoming Investor Conferences in September - StockTitan

NewAmsterdam Pharma (NASDAQ:NAMS) Sees Unusually-High Trading Volume - MarketBeat

NewAmsterdam Pharma's Cholesterol Drug To See Blockbuster Sales, Bullish Analyst Sees Massive Upside - Benzinga

NewAmsterdam Pharma (NASDAQ:NAMS) Now Covered by Analysts at Needham & Company LLC - MarketBeat

Needham Initiates Coverage of NewAmsterdam Pharma Company N.V. (NAMS) with Buy Recommendation - MSN

NewAmsterdam shares hold Buy rating on strong trial data - Investing.com

NewAmsterdam Pharma Company NV (NAMS)’s Market Momentum: Closing Strong at 16.76, Up 3.08 - The Dwinnex

You might want to take a look at NewAmsterdam Pharma Company NV (NAMS) now - SETE News

The Future of NewAmsterdam Pharma Company NV: Analyzing NAMS - The InvestChronicle

NewAmsterdam Pharma Company NV [NAMS] is 47.99% higher this YTD. Is it still time to buy? - The DBT News

NewAmsterdam Pharma (NASDAQ:NAMS) Given Consensus Recommendation of "Buy" by Brokerages - MarketBeat

NewAmsterdam Pharma CEO acquires $81k in company shares - Investing.com India

NewAmsterdam Pharma CEO acquires $81k in company shares - Investing.com

NewAmsterdam Pharma Company NV [NAMS] stock for 86,308 USD was acquired by Davidson Michael H. - Knox Daily

NewAmsterdam Pharma (NASDAQ:NAMS) Sees Strong Trading Volume - MarketBeat

NewAmsterdam Pharma CEO acquires $81k in company shares By Investing.com - Investing.com UK

Market Update: NewAmsterdam Pharma Company NV (NAMS) Sees Positive Movement, Closing at 16.27 - The Dwinnex

Are NewAmsterdam Pharma Company NV (NAMS) shares a good deal now? - US Post News

NewAmsterdam Pharma (NASDAQ:NAMS) Trading Down 2.7% - MarketBeat

FY2028 EPS Estimates for NewAmsterdam Pharma Decreased by Leerink Partnrs (NASDAQ:NAMS) - MarketBeat

FY2028 Earnings Estimate for NewAmsterdam Pharma Issued By Leerink Partnrs (NASDAQ:NAMS) - Defense World

Q3 2024 EPS Estimates for NewAmsterdam Pharma (NASDAQ:NAMS) Cut by William Blair - Defense World

NewAmsterdam Pharma Provides Corporate Update and Reports Second Quarter Financial Results - GlobeNewswire

NewAmsterdam Pharma Provides Corporate Update and Reports Second Quarter Financial Results - Yahoo Finance

NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire

Long Term Trading Analysis for (NAMS) - Stock Traders Daily

NewAmsterdam Pharma (NASDAQ:NAMS) Receives $33.25 Consensus Price Target from Brokerages - Defense World

NewAmsterdam Pharma (NASDAQ:NAMS) Rating Reiterated by Royal Bank of Canada - American Banking and Market News

Janus Henderson Group PLC Makes New $15.02 Million Investment in NewAmsterdam Pharma (NASDAQ:NAMS) - MarketBeat

NewAmsterdam Pharma (NASDAQ:NAMS) Shares Gap Down to $18.86 - Defense World

Taking a Closer Look At NewAmsterdam Pharma Company NV (NAMS) Following Its Recent Trade - Knox Daily

NewAmsterdam Pharma’s (NAMS) “Outperform” Rating Reaffirmed at Royal Bank of Canada - Defense World

Analyst Confident In NewAmsterdam Pharma's Cholesterol Drug Despite Mixed Reactions To Study Results (CORRECTED) - Benzinga

Oversold Conditions For NewAmsterdam Pharma (NAMS) - Nasdaq

Analyst Confident In NewAmsterdam Pharma's Cholesterol Drug Despite Mixed Reactions To Study Results - Benzinga

Royal Bank of Canada Reaffirms Outperform Rating for NewAmsterdam Pharma (NASDAQ:NAMS) - MarketBeat

Market Highlights: NewAmsterdam Pharma Company NV (NAMS) Ends on a Low Note at 17.25 - The Dwinnex

NewAmsterdam reports positive Phase 3 trial results of BROOKLYN By Investing.com - Investing.com Canada

NewAmsterdam Pharma (NAMS) Shares Cross Below 200 DMA - Nasdaq

NAMS’s Stochastic Averages Dip: Analyzing NewAmsterdam Pharma Company NV’s Stock Performance - The InvestChronicle

NewAmsterdam reports positive Phase 3 trial results of BROOKLYN - Investing.com

NewAmsterdam reports positive Phase 3 trial results of BROOKLYN - Investing.com India

Newamsterdam Pharma Company N V (NAMSW) 財務データ

収益

当期純利益

現金流量

EPS

NAMSWに似た銘柄